Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875269 | 0.75 | PDE10A (0.46) | HRH4HRH2HRH1HRH3ADORA2A | |
| SCHEMBL603433 | 0.69 | HRH4 (0.67) | HRH4HRH2HRH1HRH3 | |
| SCHEMBL4872472 | 0.67 | KDM4E (0.44) | HRH4HRH2HRH1HRH3ADORA2A | |
| SCHEMBL2236558 | 0.63 | PDK2 (0.41) | KDM4E | |
| SCHEMBL15727046 | 0.63 | HRH4 (0.47) | HRH4HRH2HRH1HRH3ADORA2A | |
| SCHEMBL4876229 | 0.60 | HRH4 (0.57) | HRH4HRH2HRH1HRH3 | |
| SCHEMBL14084239 | 0.59 | HRH4 (0.62) | HRH4HRH2HRH1HRH3ADORA2A | |
| SCHEMBL2165235 | 0.58 | HRH4 (0.70) | HRH4HRH2HRH1HRH3ADORA2A | |
| SCHEMBL14084044 | 0.57 | HRH4 (0.60) | HRH4HRH2HRH1HRH3ADORA2A | |
| SCHEMBL14084240 | 0.57 | HRH4 (0.60) | HRH4HRH2HRH1HRH3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | HRH4 3013/4885HRH2 2549/4885HRH1 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.